Sign In
Buy EGRX
$0.460
+0 (+0%)
At Close: Jun 03, 2026
Esports Leading The Way In Online Gaming (NASDAQ:GMBL)
06:47pm, Monday, 12'th Oct 2020
Esports Entertainment is well positioned to capture market growth. It has online gambling licenses in nearly 150 jurisdictions, a best-in-class wagering platform, hundreds of marketing affiliate partn
Oct 06, 2020 (The Expresswire) --
Granulomatosis With Polyangiitis Treatment Market 2020 Global Industry Trends, Size, Share Analysis Report. According to...
Warm Autoimmune Hemolytic Anemia (WAIHA) Market Insights, Epidemiology and Market Forecast 2030 by DelveInsight
04:49pm, Monday, 28'th Sep 2020
Sep 28, 2020 (AB Digital via COMTEX) --
Autoantibodies are antibodies that react with self-antigens. They are produced by both tissue and circulating...
Rigel Pharmaceuticals: An Interesting Asset At Reasonable Price (NASDAQ:RIGL)
05:29pm, Tuesday, 15'th Sep 2020
Rigel has an already established asset and is expecting results from another Phase 3 trial. The sale of TAVALISSE is right on its course to the sell-side expected $500 million in 2028.
Esports Entertainment Group Signs LOI to Acquire the Esports Gaming League
12:00pm, Wednesday, 26'th Aug 2020
Esports Entertainment Group, Inc. (NasdaqCM: GMBL, GMBLW) ( the “Company”), a licensed online gambling company with a focus on esports wagering and 18+ gaming,
Eagle Pharmaceuticals Announces Publication of Preclinical Study of Intranasal Dantrolene in Journal of Alzheimer’s Disease
10:50am, Wednesday, 19'th Aug 2020
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that preclinical research on dantrolene sodium was published today in the peer-reviewed Journal of Alzheimer’s D
Eagle Pharmaceuticals Inc (EGRX) Q2 2020 Earnings Call Transcript
05:30pm, Monday, 10'th Aug 2020
At this time, I'd like to welcome everyone to Eagle Pharmaceuticals' Second Quarter 2020 Earnings Results Conference Call. It's now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Rel
Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Top Estimates
12:15pm, Monday, 10'th Aug 2020
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 307.14% and 11.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Eagle Pharmaceuticals Q2 Earnings
11:06am, Monday, 10'th Aug 2020
Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) were flat in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 32.14% year over year to $0.57, which
Eagle Pharmaceuticals Reports Second Quarter 2020 Results
10:50am, Monday, 10'th Aug 2020
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced financial results for the three and six months ended June 30, 2020.
Eagle Pharmaceuticals Reports Second Quarter 2020 Results
12:00am, Monday, 10'th Aug 2020
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and six months ended June 30, 20
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Provention Bio: Undervalued And Overlooked Biotech Company - Diabetes Is Not Going Away Anytime Soon (NASDAQ:PRVB)
02:10pm, Tuesday, 04'th Aug 2020
Teplizumab's At-Risk PHASE II trial showed promising results in significantly delaying the onset of T1D in pre-symptomatic patients by a median of three years relative to placebo.
Edwards Lifesciences Shows Surprising Resilience, And TAVR Remains A Growth Market (NYSE:EW)
10:24am, Tuesday, 04'th Aug 2020
TAVR procedures were surprisingly resilient in the second quarter, driving a large revenue and profit beat for Edwards.
